



Respiratory


Respiratory drug development and commercialisation encompass improvements in existing classes of systemic and inhaled treatments as well as novel agents for common and rare respiratory conditions. Finding effective and safe new classes of drugs to treat asthma and COPD remains difficult. tranScrip teams have expertise in all major respiratory indications from asthma, COPD and allergy to orphan indications such as cystic fibrosis or idiopathic pulmonary fibrosis. We are helping our clients address clinical and regulatory challenges, differentiate their products and realise drug development and lifecycle goals.

Visit [transcrip-group.com](https://www.transcrip-group.com)



Diverse Programmes Effective Execution

A snapshot of our recent projects



tranScrip is a specialist pharmaceutical consultancy, delivering expert medical, clinical and regulatory solutions through a multidisciplinary team that helps you transform great science into valuable medicines.

tranScrip gives you direct access to senior specialist, hands-on drug development experts, who will work alongside you to design and deliver programmes that create real value. Drawing on years of senior leadership experience across global pharma and biotech, our experts act as a flexible extension of your team, providing scalable support across the lifecycle when and where it is needed.



Discovery & Pre-clinical

Select the right asset and get ready for first-in-human with confidence



Early Clinical

Design and deliver programmes that generate robust data and clear proof-of-concept



Late Clinical

Design and deliver programmes that stand up to regulatory and commercial scrutiny



Registration & Approval

Secure regulatory approval and successfully bring your medicine to market